Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.38 |
| ▸ | RELA | Q04206 | 2/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899464 | 0.83 | EPHX2 (0.43) | NFKB1NFKB2RELAGAAEPHX2 | |
| SCHEMBL29854574 | 0.77 | GAA (0.39) | KDM4DSIRT2SIRT1NFKB1NFKB2 | |
| SCHEMBL1562606 | 0.73 | RIPK1 (0.49) | — | |
| SCHEMBL1562605 | 0.73 | RIPK1 (0.49) | — | |
| SCHEMBL1561668 | 0.72 | GAA (0.50) | KDM4DSIRT2SIRT1GAAEPHX2 | |
| SCHEMBL1561671 | 0.72 | GAA (0.50) | KDM4DSIRT2SIRT1GAAEPHX2 | |
| SCHEMBL31075203 | 0.72 | KMT2A (0.46) | KDM4DSIRT2SIRT1NFKB1NFKB2 | |
| SCHEMBL9220504 | 0.71 | SIRT2 (0.45) | SIRT2SIRT1 | |
| SCHEMBL9220493 | 0.71 | SIRT2 (0.45) | SIRT2SIRT1 | |
| SCHEMBL9220485 | 0.71 | SIRT2 (0.45) | SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509950-B1 | 5-Amino-4-hydroxypentoyl amides | JANSSEN R & D IRELAND (IE) | 2015-02-25 | — | — | EP | disclosed |
| US-20120295920-A1 | 5-AMINO-4-HYDROXYPENTOYL AMIDES | JANSSEN SCIENCES IRELAND UC (IE) | 2012-11-22 | — | — | US | disclosed |
| WO-2011070131-A1 | 5-AMINO- 4-HYDROXYPENTOYL AMIDES | TIBOTEC PHARMACEUTICALS (IE) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295920-A1 | 5-AMINO-4-HYDROXYPENTOYL AMIDES | C1S, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-10 | HCRTR2 3548/4885KDM4D 966/4885SIRT2 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.